Loading...

EXEL EXELIXIS INC Expansion Plans 8-K Filing

XLXS

XL

EXELIXIS INC

(EXEL)

2024 8-K

Show Summary

Show Summary

Financial Statements

Stock Award Program

Financial Results

Financial Results

Financial Results

Clinical Collaboration

Financial Results and Stock...

Annual Meeting Approval

Settlement and License Agre...

Complaint filed against Cip...

Financial Results Announcement

Departure of Directors

Financial Results Announcement

Earnings Release, Restructu...

Amendments to Change in Con...

Financial Results Announcement

Departure of Directors

Departure of Directors

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Resignation of Director

Departure of Directors

External Links:

Exelixis, Inc. has partnered with Merck to conduct clinical trials combining its drug zanzalintinib with Merck's KEYTRUDA and WELIREG for treating head and neck and renal cell cancers, with Merck supplying KEYTRUDA and funding part of the trials.

AI Assistant

EXELIXIS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.